Artificial Intelligence (AI) has become one of the most talked about issues in the recent years and is still a hot topic today. Starting from AlphaGo defeating Lee Sedol and Jie Ke, AI has begun to lead the financial, medical, automotive and retail industries into a whole new era. Especially in the medical industry, after several years of development, with the support of big data accumulation, algorithms based on multiple models, and especially under the leadership of medical technology experts like Lam Yeung Kit Billy, medical has become one of the representative industries to take the lead in the era of intelligence.
Lam Yeung Kit Billy is the Director of Breast Care Centre of Hong Kong Baptist Hospital and a famous surgeon and breast cancer specialist in Asia. Over the years, he has achieved outstanding achievements in theoretical research and clinical practice. Through in-depth research on a number of technologies in the field of artificial intelligence such as knowledge graph, deep learning, expert system, pattern recognition, etc., he has successfully developed numerous extremely advanced and intelligent medical technological achievements for some important issues that need to be improved in the medical service industry, and has achieved great success in the practical application, which has been unanimously recognized and praised by the industry experts.
“Among many fields, the combination of medical industry and artificial intelligence has become the focus of market attention. Artificial intelligence in medical has been able to take the lead mainly because there is currently an extreme shortage and unbalanced distribution of medical resources. In China, for example, the training cycle of medical talents is too long and costly, and there is a shortage of excellent doctors, which has led to an urgent need for intelligent information technology of medical. In fact, China is not the only country facing a shortage of doctors. The United States will also experience a shortage of 60,000 to 90,000 doctors in the next decade, and similar problems exist in aging Switzerland and Japan, as well as in sparsely populated Australia. Especially since the COVID-19 has spread globally, such problems have become more prominent. In short, addressing the lack of supply of medical resources is the fundamental motivation for the combination of artificial intelligence and medical industry.” Lam Yeung Kit Billy said.
As a leader in promoting innovation in the integration of artificial intelligence and medical, Lam Yeung Kit Billy has contributed numerous leading technological achievements to the industry in medicine development, disease detection and diagnosis, and surgical operations, greatly reducing the burden on doctors, patients, the government and society. For example, the “Intelligent Control System of Minimally Invasive Treatment Equipment Based on Pattern Recognition V1.0”, which is applied to intelligent medical robots, is specifically designed for minimally invasive surgeries that require incision control of a few millimeters, as it can be finer and more stable than human hands, and takes less time to operate. At present, the core algorithm of this technology has been adopted by many medical technology companies. For example, Verb Surgical, which was jointly established by Alphabet, the parent company of Google, and Johnson & Johnson, produced an intelligent robot for the treatment of breast disease, kidney disease, eye disease, cardiovascular and cerebrovascular disease surgery. After introducing the core computing model of Lam Yeung Kit Billy’s technology, after half a year of testing and application, the operation success rate of the intelligent robot reached 100%, and the average completion time of each operation was shortened by more than 60%. It is understood that this technology has been introduced by Alibaba, Tencent, Baidu, IFLYTEK, BGI and other well-known Internet companies’ medical boards, and overseas companies including IBM, Google, Apple, Microsoft and Amazon have also introduced this technology. These companies are seizing the opportunity of artificial intelligence to complete the transformation of intelligent information technology of medical, and thus intelligent medical robots capable of performing minimally invasive surgery are naturally one of their key goals.
The above-mentioned technology companies in the field of artificial intelligence investment scale has reached nearly one hundred billion dollars, of which intelligent medical accounted for twenty percent. Following the launch of IBM’s famous Watson robot at the end of 2016 (which adopts deep learning technology and is mainly used to assist Pfizer in immuno-oncology medicine development), the intelligent medical-pharmaceutical technology has entered a new phase of development. The world’s major economies as well as leading medical technology companies continue to make efforts in this field. By 2017, Japan’s online telemedicine system CLINICS has introduced more than 350 medical institutions, allowing for appointments, consultations, video consultations, payments, prescriptions and delivery of pharmaceuticals through the Internet. The Australian government has invested a total of 45 million Australian dollars in the implementation of the BioMedTech Horizons program, aiming at developing advanced equipment in medical wearable, telemedicine and digital and intelligent personalized medicine. In 2019, IBM Australia team developed a new machine learning algorithm that can predict the content of β-amyloid in spinal fluid only by checking the levels of four proteins in the blood, with an accuracy rate of 77%.
As a pioneer of intelligent technology in medical industry, Lam Yeung Kit Billy also published the “Prescription Customization and Drug Development Decision-making System Based on Knowledge Graph V1.0” at the beginning of this year. By establishing the mapping relationship between the physical and chemical properties of medicines and the laws of molecular biology, physiology and pathology, this technological achievement can quickly analyze a large amount of text data and refer to laboratory data, clinical reports and relevant data from scientific publications to automatically deduce and generate prescription customization and medicine development solutions for patients or a certain type of disease, realizing the value of artificial intelligence as a new tool. Dr. Bowen Zhou, former Chief Scientist of IBM Watson Group and current Chairman of JD.com Technology Committee, President of JD Smart Cloud and President of JD Intelligent Research Institute, spoke highly of this technology. He said: “This technological achievement of Lam Yeung Kit Billy has surpassed the Watson robot in terms of the innovation of the technical architecture, the difficulty of the core algorithm, and the breadth and accuracy of the system application. This is a groundbreaking technological achievement. IBM has led the first half of this era of change in AI + medical, while the leader of the second half will definitely be Mr. Lam Yeung Kit Billy.”
In addition to the above two technological achievements, Lam Yeung Kit Billy has also published the “Disease Risk Analysis System Based on Individual Genetic Testing V1.0” and “Multi-purpose Expert System for the Diagnosis and Treatment of Breast Diseases V1.0” in the areas of intelligent treatment and disease risk analysis. The intelligent technologies involved include information retrieval, machine learning, cognitive technology, natural language understanding, automatic reasoning, and expert systems, which help doctors to make more accurate and rapid examinations in the prediction of disease risk for various diseases and the in-depth diagnosis and treatment of breast diseases.
“In my opinion, artificial intelligence is of great significance to the transformation of the medical industry. It is not just a technological innovation, but a change in the productivity of the medical industry. The previous development of technology was to strengthen the doctor’s senses such as vision and touch, while AI technology makes the whole medical industry chain more optimized for the benefit of more patients.” Lam Yeung Kit Billy said.
Reporter: Jennifer Ross